[BidClub_]

PERSON DIRECTORY

Molly O'Shea

Host of Sourcery. Molly O'Shea appears in 41 indexed conversations across Sourcery. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.

41 EPISODES1 SHOW
13 episodes3 active
Language
SourceryEN · 56 min

Apollo’s Yahoo Playbook, 5 Years After the $5B Deal

Jim LanzoneMolly O'Shea

Lanzone says Apollo has largely recovered its $4.8 billion Yahoo cost through early cash returns and disposals including AOL.The reset shut loss-making ad tech that cost hundreds of millions annually and opened inventory to competing demand, while retaining DSP.Scout restores owned search, but Lanzone makes no IPO commitment and hesitates to call Yahoo’s audience distribution a moat.

SourceryEN · 70 min

Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX

Molly O'SheaNworah Ayogu

Thrive’s healthcare thesis is that AI may shift bottlenecks from molecule generation to validation, trials, manufacturing, and commercialization.Cadence cites 25% fewer hospitalizations, over-80% more controlled-blood-pressure patients, nearly one-point lower A1C, and $2.5 million in weekly Medicare savings across 100,000+ monitored patients.Neuralink and OpenAI show upside, while clinical processes and manufacturing capacity remain unresolved constraints.

SourceryEN · 85 min

USV’s New $900M Fund: Fred Wilson, Rebecca Kaden & Mike Mignano

Fred WilsonRebecca KadenMichael MignanoMolly O'Shea

USV’s $900 million fund targets 30-40 companies with $10 million-$30 million Series A checks as larger rounds and scaling costs reshape venture.Its AI thesis spans applications, infrastructure, physical AI, and energy, while usage retention, compute costs, inference subsidies, distribution, interoperability, trust, and leadership concentration remain key tests.

SourceryEN · 58 min

Annie Lamont: $14B Managed, 70+ Exits, 15 IPOs, 7x Midas Investor

Jonathan SiddharthMolly O'Shea

Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.

SourceryEN · 75 min

Bending Spoons Is Coming for Silicon Valley, with CEO Luca Ferrari

Luca FerrariMolly O'Shea

Bending Spoons’ edge is an integrated operating model that standalone owners cannot economically reproduce.Its 50-plus proprietary technologies, nearly 1,000-person core team, and debt-funded permanent ownership support claimed annual savings above $100 million and $4 million revenue per core Spooner.Airtable’s approximately $1.3 billion enterprise value reflects the underwriting test, while AI startup valuations and unmeasured AI capabilities remain key risks to monitor.

SourceryEN · 57 min

Benchmark's AI Bets: Cerebras, Sierra, Legora, Fireworks, Starcloud, Gumloop..

Everett RandleMolly O'Shea

AI is breaking the spreadsheet playbook: billion-dollar businesses can still lack unit economics or durable differentiation, and scale may increase impairment risk.Inference monetization can drive revenue from 1 to 30 to 300, while agents shift purchases toward intelligence or economic output.Frontier labs retain pricing power if recursive self-improvement works, but face a 95%-as-good open-source squeeze if capabilities plateau.

SourceryEN · 57 min

General Catalyst's First-Ever Quarterly Review | CEO Hemant Taneja

Hemant TanejaMolly O'Shea

Anthropic is adding $10 billion of revenue a month and NVIDIA added $1 trillion of market cap in 100 days, highlighting AI-era scale concentration.GC’s counter-bet spans seed, Creation, and Customer Value Fund strategies, while 15x-to-3x revenue-multiple compression could leave even doubled-EBITDA software equity unrecovered.Leverage coming due in the next five years makes AI transformation opportunities and durability uncertainty key variables to monitor.

SourceryEN · 97 min

Wiz: $6M Seed → $32B Exit | Inside the Biggest Cybersecurity Deal Ever

Molly O'SheaGili Raanan

Wiz’s $32B deal remains pending after European approval Monday, while its biggest revenue quarter supports Raanan’s view that “we probably sold low.”Concentrating pain, authority, user, and budget with the CISO compressed sales to 45 minutes and produced $1M, $2M, $8M, and $24M across four quarters.Raanan warns AI could bring cybersecurity’s darkest period in the next 10 years, with self-aware agents and mega-agents challenging human defense.

SourceryEN · 58 min

Inside Thrive Capital: Investing in OpenAI, Wiz, Cursor, Nudge, Physical Intelligence

Philip ClarkMolly O'Shea

Thrive’s $29B OpenAI entry reflected belief in GPT-4 and a claimed moat in generating successive large-model paradigms; reported valuation later reached $500B, with users surpassing a billion.Cursor grew from low-single-digit millions of ARR to hundreds of millions in 18 months, while Wiz paired six-figure deals closing in weeks or months with almost no churn.The next catalysts are reinforcement learning entering production software and intelligent hardware targeting well north of 50% of global GDP.

SourceryEN · 70 min

Inside $6.8B+ AUM Fund Behind 80+ Public Companies, 165+ M&A

Molly O'SheaDeedy Das

Goodfire, staffed by early Anthropic, DeepMind, and OpenAI interpretability researchers, is Das’s marquee “brain surgery for AI models” bet.Demographic decline makes AI for unhireable insurance, trucking, and logistics jobs a need-now market, not a future-capability wager.Carta’s 30% AI Series A premium may reward genuinely deep teams, while over-raising and RL bottlenecks keep pricing and timelines unresolved.